Cargando…
Towards Commercial Production of Sponge Medicines
Sponges can provide potential drugs against many major world-wide occurring diseases. Despite the high potential of sponge derived drugs no sustainable production method has been developed. Thus far it is not fully understood why, when, where and how these metabolites are produced in sponges. For th...
Autores principales: | , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Molecular Diversity Preservation International
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2810229/ https://www.ncbi.nlm.nih.gov/pubmed/20098610 http://dx.doi.org/10.3390/md7040787 |
_version_ | 1782176663389339648 |
---|---|
author | Koopmans, Marieke Martens, Dirk Wijffels, Rene H. |
author_facet | Koopmans, Marieke Martens, Dirk Wijffels, Rene H. |
author_sort | Koopmans, Marieke |
collection | PubMed |
description | Sponges can provide potential drugs against many major world-wide occurring diseases. Despite the high potential of sponge derived drugs no sustainable production method has been developed. Thus far it is not fully understood why, when, where and how these metabolites are produced in sponges. For the near future sea-based sponge culture seems to be the best production method. However, for controlled production in a defined system it is better to develop in vitro production methods, like in vitro sponge culture or even better sponge cell culture, culture methods for symbionts or the transfer of production routes into another host. We still have insufficient information about the background of metabolite production in sponges. Before production methods are developed we should first focus on factors that can induce metabolite production. This could be done in the natural habitat by studying the relation between stress factors (such as predation) and the production of bioactive metabolites. The location of production within the sponge should be identified in order to choose between sponge cell culture and symbiont culture. Alternatively the biosynthetic pathways could be introduced into hosts that can be cultured. For this the biosynthetic pathway of metabolite production should be unraveled, as well as the genes involved. This review discusses the current state of sponge metabolite production and the steps that need to be taken to develop commercial production techniques. The different possible production techniques are also discussed. |
format | Text |
id | pubmed-2810229 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2009 |
publisher | Molecular Diversity Preservation International |
record_format | MEDLINE/PubMed |
spelling | pubmed-28102292010-01-22 Towards Commercial Production of Sponge Medicines Koopmans, Marieke Martens, Dirk Wijffels, Rene H. Mar Drugs Article Sponges can provide potential drugs against many major world-wide occurring diseases. Despite the high potential of sponge derived drugs no sustainable production method has been developed. Thus far it is not fully understood why, when, where and how these metabolites are produced in sponges. For the near future sea-based sponge culture seems to be the best production method. However, for controlled production in a defined system it is better to develop in vitro production methods, like in vitro sponge culture or even better sponge cell culture, culture methods for symbionts or the transfer of production routes into another host. We still have insufficient information about the background of metabolite production in sponges. Before production methods are developed we should first focus on factors that can induce metabolite production. This could be done in the natural habitat by studying the relation between stress factors (such as predation) and the production of bioactive metabolites. The location of production within the sponge should be identified in order to choose between sponge cell culture and symbiont culture. Alternatively the biosynthetic pathways could be introduced into hosts that can be cultured. For this the biosynthetic pathway of metabolite production should be unraveled, as well as the genes involved. This review discusses the current state of sponge metabolite production and the steps that need to be taken to develop commercial production techniques. The different possible production techniques are also discussed. Molecular Diversity Preservation International 2009-12-02 /pmc/articles/PMC2810229/ /pubmed/20098610 http://dx.doi.org/10.3390/md7040787 Text en © 2009 by the authors; licensee Molecular Diversity Preservation International, Basel, Switzerland http://creativecommons.org/licenses/by/3.0 This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/). |
spellingShingle | Article Koopmans, Marieke Martens, Dirk Wijffels, Rene H. Towards Commercial Production of Sponge Medicines |
title | Towards Commercial Production of Sponge Medicines |
title_full | Towards Commercial Production of Sponge Medicines |
title_fullStr | Towards Commercial Production of Sponge Medicines |
title_full_unstemmed | Towards Commercial Production of Sponge Medicines |
title_short | Towards Commercial Production of Sponge Medicines |
title_sort | towards commercial production of sponge medicines |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2810229/ https://www.ncbi.nlm.nih.gov/pubmed/20098610 http://dx.doi.org/10.3390/md7040787 |
work_keys_str_mv | AT koopmansmarieke towardscommercialproductionofspongemedicines AT martensdirk towardscommercialproductionofspongemedicines AT wijffelsreneh towardscommercialproductionofspongemedicines |